Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Palobiofarma (Details)

v3.21.1
Royalty Purchase Agreements - Palobiofarma (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 26, 2019
USD ($)
item
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Agreements      
Payments to acquire milestones and royalties   $ 13,500  
Long-term royalty receivables   48,075 $ 34,575
Impairment of long-term royalty receivable   0 $ 0
Palobiofarma, S.L. | Royalty Purchase Agreement      
Agreements      
Number of drug candidates | item 6    
Payments to acquire milestones and royalties $ 10,000    
Long-term royalty receivables 10,000    
Impairment of long-term royalty receivable   $ 0  
Palobiofarma, S.L. | Royalty Purchase Agreement | Silicon Valley Bank Loans      
Agreements      
Proceeds from issuance of long-term debt $ 5,000